Court Says Fresenius Can Pull Out of Akorn Acquisition

A Delaware court on Monday sided with Fresenius in its bid to pull out of a planned $4.3 billion merger with Akorn because of alleged fraud and falsified testing data submitted to the FDA.
Source: Drug Industry Daily